Mice infected with several T. cruzi strains (susceptible, partially susceptible, and not susceptible to Bz) were treated with fexinidazole and the fexinidazole regimens had an acceptable safety profile in this study but did not prove effective against T. cruzi infection. Therefore, the development of fexinidazole monotherapy for treating T. cruzi infection has been stopped. In spite of the difficulties related to the clinical aspects, the development of antiparasitic compounds has been recently addressed by both industrial and academic groups.